TrialsgrambetaRCTs are beautiful

SELECT

2023

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

In 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.

Result

Efficacy: CV death, MI or strokeHR 0.8

Below 1 favours semaglutide, above 1 favours placebo.

Event rates
Absolute difference
1.5 points

The absolute difference is derived from the event rates.

Also reported: Mean weight loss 9.4 %.

Original publication
Subtopic
GLP-1 RA
Design
Double-blind RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.doi 10.1056/NEJMoa2307563

Discussion & critique

First trial to show cardiovascular risk reduction from treating obesity itself, without diabetes. How much of the benefit is weight loss versus direct drug effect is unresolved.

Discussed in podcasts